Gene therapy for cancer: From the laboratory to the patient

Digestive Diseases and Sciences

Volumn 45, Issue 6, 2000, Pages 1045-1052

  Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cancer; Gene therapy; Vector

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; CANCER GENETICS; CLINICAL PRACTICE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN ADENOVIRUS 2; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TUMOR REJECTION; TUMOR SUPPRESSOR GENE;

CLINICAL TRIALS; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0034124526     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005592309466     Document Type: Review

References (72)

1. 1. Rosenberg SA: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Sci Am 1:90-100, 1995
2. 2. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
3. 3. Habib NA, Ding S, Ei-Masry R, Dalla Serra G, Mikhail NE, Izzi G: Contrasting effects of direct p53 DNA injection in primary and secondary liver tumors. Tumor Target 1:295-298, 1995
4. 4. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C: Interleukin-2 gene therapy in a patient with glioblastoma: Using a retrovirus vector. Gene Ther 2:164-167, 1995
5. 5. Raftopoulos J, Kouraklis G: Dysfunction of the E-cadherin/catenin cell adhesion cascade in epithelial cancers. Oncol Rep 3:793-803, 1996
6. 6. Mastrangelo MJ, Schultz S, Kane M: Newer immunologic approaches to the treatment of patient with cancer. Semin Oncol 15:589-594, 1988
7. 7. Smith KA: Interleukin 2: Inception, impact and implications. Science 240:1169-1170, 1988
8. 8. Trial: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 3:75-90, 1992
9. 9. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256:1550-1552, 1992
10. 10. Zhang Y: Retroviral vector-mediated transduction of K-ras antisense RNA into human cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993
11. 11. Friedmann T: Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70(suppl):1810-1817, 1992
12. 12. Samara G, Sawicki MP, Hurwitz M, Passaro E: Molecular biology and therapy of disease. Am J Surg 165:720-727, 1993
13. 13. Kouraklis G: Progress in cancer gene therapy. Acta Oncol 38:675-683, 1999
14. 14. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strans M: Adenovirally transferred p16 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3:316-319, 1997
15. 15. Crystal RG: Transfer of gene to humans: Early lessons and obstacles to success. Science 270:404-410 1995
16. 16. Coffin JM: Retroviradae and their replication. In Virology, 2nd ed. BN Fields, DM Knipe (eds). New York, Raven Press, 1990.
17. 17. Watson JD, Hopkins NH, Roberts JW, Steitz JA, Weiner AM: Molecular Biology of the Gene, 4th ed. New York, Benjamin-Cummings, 1988
18. 18. Miller AD: Retrovirus packaging cells. Hum Gene Ther 1:5-14, 1990.
19. 19. Herrmann F: Cancer gene therapy: Principles, problems, and perspectives. J Mol Med 73:157-163, 1995
20. 20. Gelinas C, Temin HM: Nondefective spleen necrosis virus-derived vectors define the upper size limit for packaging reticuloendotheliosis viruses. Proc Natl Acad Sci USA 83:9211-9215, 1986
21. 21. Letvin NL: Progress in the development of an HIV-1 vaccine. Science 280:1875-1879, 1998
22. 22. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third generation lentivirus vector with a contitional packaging system. J Virol 72:8463-8471, 1998
23. 23. Horwitz MS: Adenoviridae and their replication. In Virology, 2nd ed. BN Fields, DM Knipe (eds). New York, Raven Press, 1990, pp 1679-1721
24. 24. Trapnell BC, Gorziglia M: Gene therapy using adenoviral vectors. Curr Opin Biotechnol 5:617-625, 1994
25. 25. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91:6196-6200, 1994.
26. 26. Engelhardt JF, Litzky L, Wilson JM: Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. Hum Gene Ther 5:1217-1229, 1994
27. 27. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22, 1996
28. 28. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci USA 93:5731-5736, 1996
29. 29. Bridge E, Medghalchi S, Ubol S, Leesong M, Ketner G: Adenovirus early region 4 and viral DNA synthesis. Virology 193:794-801, 1993
30. 30. Wang Q, Jia XC, Finer MH: A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 2:775-783, 1995
31. 31. Wang Q, Finer MH: Second generation adenovirus vectors. Nat Med 2:714-716, 1996
32. 32. Gao GP, Yang Y, Wilson JM: Biology of adenoviral vectors deleted of E1 and E4 for liver-directed gene therapy. J Virol 70:8934-8943, 1996
33. 33. Latchman DS: Herpes simplex virus vectors for gene therapy. Mol Biotechnol 2:179-195, 1994
34. 34. Neve RL, Geller AJ: A defective herpes simplex virus vector system for gene delivery into the brain: Comparison with alternative gene delivery systems and usefulness for gene therapy. Clin Neurosci 3:262-267, 1996
35. 35. Turner SL, Jenkins FJ: The roles of herpes simplex virus in neuroscience. J Neurovirol 3:110-125, 1997
36. 36. Latchman DS: Herpes simplex virus vector for gene therapy. Mol Biotechnol 2:179-195, 1994
37. 37. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA: Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 2:151-159, 1995
38. 38. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555, 1994
39. 39. Zhu N, Liggitt D, Liu Y, Debs R: Systematic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211, 1993
40. 40. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL: Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 90:11548-11552, 1993
41. 41. Bunnell BA, Askari FK, Wilson JM: Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 18:559-569, 1992
42. 42. Cotten M, Wagner E, Zatloukal K, Philips S, Curiel DT, Birnstiel ML: High-efficiency receptor-mediated delivery of small and large (48 kb) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89:6094-6098, 1992
43. 43. Trial: Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3:339-410, 1992
44. 44. Toneguzzo F, Keating A: Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field mediated DNA transfer. Proc Natl Acad Sci USA 83:3496-3499, 1986
45. 45. Sekhar M, Kotani H, Doren S, Agarwal R, McGarrity GJ, Dunbar CE: Retroviral transduction of CD34-enriched hematopoietic progenitor cells under serum-free conditions. Hum Gene Ther 7:33-38, 1996
46. 46. Vile RG, Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53:3860-3864, 1993
47. 47. Cheng L, Ziegelhoffer PR, Yang NS: In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 90:4455-4459, 1993
48. 48. Nicolet CM, Burkholder JK, Gan J, Culp J, Kashmiri SV, Schlom J: Expression of a tumor-reactive antibody-interleukin-2 fusion protein afler in vivo particle-mediated gene delivery. Cancer Ther 2:161-170, 1995
49. 49. Sobol R, Scanlon KJ: Clinical protocols list. Cancer Gene Ther 2:225-234, 1995
50. 50. Friedmann T: Progress toward human gene therapy. Science 244:1275-1281, 1989
51. 51. Miller AD: Human gene therapy comes of age. Nature 357:455-460, 1992
52. 52. Anderson WF: Human gene therapy. Science 256:808-813, 1992
53. 53. Friedmann T: A brief history of gene therapy. Nature Genet 2:93-98, 1992
54. 54. Gutierrez AA, Lemoine NR, Sikora K: Gene therapy for cancer. Lancet 339:715-720, 1992
55. 55. Anderson WF: Gene therapy for cancer. Hum Gene Ther 5:1-2, 1994
56. 56. Eglitis M, Kantoft P, Gilboa E, Anderson WF: Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 230:1395-1398, 1985
57. 57. Trial: The N2-TIL human gene transfer clinical protocol. Hum Gene Ther 1:73-92, 1990
58. 58. Trial: The ADA human gene therapy clinical protocol. Hum Gene Ther 1:327-362, 1990
59. 59. Anonymous: Cancer gene therapy annuall conference 1997: Trends and news. Hum Gene Ther 9:283-286, 1998 (editorial)
60. 60. Anonymous: Clinical protocols. Cancer Gene Ther 2:67-74, 1995 (editorial)
61. 61. ORDA Reports: Recombinant DNA Advisory Committee (RAC) data management report - December 1994. Hum Gene Ther 6:535-548, 1995
62. 62. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human MDRI. Science 257:99-103, 1995
63. 63. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L: Retrovirus mediate expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea induced toxicity in vitro and in vivo. Cancer Res 55:2608-26014, 1995
64. 64. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87:2579-2587, 1996
65. 65. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA: Cell cycle arrest and inhibition of tumor cell proliferation by the p16/ INK4 gene mediated by an adenovirus vector. Cancer Res 55:3250-3253, 1995
66. 66. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C: Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56:2245-2249, 1996
67. 67. Dranoff G: Cancer gene therapy: Connecting basic research with clinical inquiry. J Clin Oncol 16:2548-2556, 1998
68. 68. Bunnell BA, Askari FK, Wilson JM: Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 18:559-569, 1992
69. 69. Curiel DT, Wagner E, Cotten M, Birnstiel ML, Agarwal S, Li C: High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 3:147-154, 1992
70. 70. Kasahara N, Dozy AM, Kan YW; Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373-1376, 1994
71. 71. Roth JA: Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53. Hum Gene Ther 7:861-874, 1996
72. 72. Ghazal P, Lubon H, Fleckenstein B, Hennighausen L: Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci USA 84:3658-3662, 1987